Abstract
Aim. Eradication of hepatitis C virus (HCV) is still challenging even if interferon- (IFN-) free regimens with direct-acting antiviral agents (DAAs) for HCV-infected individuals are available in clinical practice. IFNL4 is a newly described protein, associated with human antiviral defenses. We investigated whether IFNL4 ss469415590 variant has an effect on the prediction of treatment response in HCV-infected patients treated with IFN-including regimens. Patients and Methods. In all, 185 patients infected with HCV genotype 1 treated with peg-IFN plus ribavirin, with or without telaprevir, were genotyped for IFNL4 ss469415590. We retrospectively investigated whether the role of IFNL4 ss469415590 variant and other factors could predict sustained virological response (SVR) in Japanese patients infected with HCV genotype 1. Results. There were 65.7%, 31.5%, and 2.8% patients in the IFNL4 ss469415590 TT/TT, TT/-G, and -G/-G groups, respectively. SVR rates were 82.1% or 49.3% in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Conclusion. In the era of DAAs, measurement of IFNL4 ss469415590 variant could help the prediction of SVR in Japanese HCV genotype 1 infected individuals treated with IFN-including regimens.
Highlights
Chronic hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma (HCC) and end-stage liver disease requiring liver transplantation in the United States [1, 2]
We reported that IFNL3 rs8099917 was useful for the prediction of sustained virological response (SVR) in patients infected with HCV genotype 1 [9]
We reported that IFNL3 induces IFN-stimulated genes (ISGs) such as IFN-γ-inducible protein (IP-10) that are reportedly associated with the progression of HCV-related pathogenesis and antiviral activities against HCV [12]
Summary
Chronic hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma (HCC) and end-stage liver disease requiring liver transplantation in the United States [1, 2]. HCV infection is a world health problem. The former standard treatment with peginterferon (pegIFN) plus ribavirin led to ∼50% and ∼80% sustained virological response (SVR) rates in patients infected with HCV genotypes 1 and 2, respectively [4]. Since 2011, peg-IFN plus ribavirin with telaprevir or boceprevir has been available in the United States as well as that with telaprevir in Japan. These treatments resulted in higher SVR rates (∼70% and ∼80% for treatment-naıve patients and previous treatment relapsers, resp.) in HCV genotype 1 infected patients [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
